lutetium Lu 177-DTPA-omburtamab (Pending FDA Approval)

Brand and Other Names:Omblastys
Sections

Dosing & Uses

AdultPediatric

See pediatric dosing and uses

Neuroblastoma

Pending FDA approval for radioimmunotherapy in pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma

Next:

Pharmacology

Mechanism of Action

Radiolabeled monoclonal antibody conjugate

Upon intracerebroventricular administration, omburtamab binds to B7-H3 expressed on certain tumor cells; upon binding, lutetium Lu 177-DTPA-omburtamab delivers a cytotoxic dose of beta radiation to B7-H3-expressing cells

B7-H3 is overexpressed on certain tumor cell types and on various immune cells, but is minimally expressed by normal human tissues; B7-H3 is a negative regulator of T-cell activation; its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and is correlated with poor prognosis

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.